Cargando…
免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143967/ https://www.ncbi.nlm.nih.gov/pubmed/33819969 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04 |